Pharma Pricing and Reimbursement and Market Access Risk Scores (MARS) by Region – Overview of 2022 and Outlook for 2023

Powered by

Access in-depth insight and stay ahead of the market

Accessing the in-depth insight from the ‘Pharma Pricing and Reimbursement’ report can help you –

  • Understand the latest/global outlook for pricing and market access reforms in the pharmaceutical industry such as HTA reforms.
  • Understand price cuts/increases and reimbursement restrictions around the world through unique price intelligence and data.
  • Identify the potential regions (Europe, Latin America, APAC and North America) and target the markets best suited to strategic focus.
  • Benchmark launch sequence and P&R strategies with the risk scores for each potential country, and how they compare with events-driven risk.
  • Anticipate expected changes in the market and adjust your business development strategies.

How is the ‘Pharma Pricing and Reimbursement’ report different from other reports in the market?

  • The report provides a summary of Market Access Risk Scores (MARS) data and analysis of 75 countries for Q1 2023.
  • It highlights the summary of POLI Indicators Data and Analysis for Q1 2023, which provides important insight into changes and updates in critical benchmark indicators such as the average launch sequence.
  • It provides a list of the key issues (P&R Policy Reforms, HTA Reforms, Market Access Risk).
  • The report gives a detailed analysis of the key players in this sector (e.g, Pfizer, AstraZeneca, Merck & Co, J&J, Novartis, Roche, and Sanofi) 

We recommend this valuable source of information to anyone involved in:

  • Pharma Manufacturers (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease) / Distributors
  • Pharmacies
  • Parallel Trade Organisations
  • Clinical Research Organisations (CROs)
  • Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)
  • Healthcare Organisations (Payers, HTA Bodies, Reimbursement Groups, Government Healthcare Organizations)

To Get a Snapshot of the Pharma Pricing and Reimbursement Market Report, Download a Free Report Sample

Pharma Pricing and Reimbursement Market Overview

The global market access risk score (MARS) has significantly increased in the first quarter of 2023 while remaining at an elevated risk level of 2.371. 2023 sees an increasing standoff between the pharma industry and the government. As governments look to address budget deficits and inflation, the pharma sector has been targeted as a profitable industry even during the COVID-19 pandemic.

The pharma pricing and reimbursement (P&R) and market access risk report provide an executive summary of healthcare expenditure and pharmaceutical sales forecasts from its Q1 2023 forecast cycle. For this quarterly update, GlobalData has updated the events risk ratings for the past 3 months captured in our qualitative measures, along with macroeconomic, political, legal environment, demographic and social structure effectiveness, technology and infrastructure, and environment risks. These factors are reflected in the quantitative measures. GlobalData has also included a look back at the key pricing and market access trends of 2022 and how they will define the outlook of the pharma industry in2023.

Global Market Access Risk Evolution 2021-2023

Global Market Access Risk Evolution (2021-2023)

To get more insights into the market access risk evolution, download a free report sample

Analysis Period Q1 2021 – Q1 2023
Key Regions Latin America, North America, Europe, Asia-Pacific, and Middle East & Africa

Pricing and Market Access Trends

The efforts to safeguard medicines supplies will continue, and some advanced markets are likely to offer pricing and reimbursement incentives to domestically produced medicines. Such small instances of pricing and reimbursement flexibility will be balanced by efforts to secure pharmaceutical savings in other areas.

For example, initiatives in the US include boosting the use of biosimilars (with one major health plan already announcing plans to add biosimilar Humira to its formulary), and direct government price negotiation (the first in US history) of selected Medicare medicines under the Inflation Reduction Act.

2023 will continue to see price hikes in response to the ongoing drug shortages due to the Russo-Ukrainian conflict, rising inflation rates, and increased cost of manufacturing. Countries such as Turkey, Greece, and Germany have already begun placing measures to incentive generics or apply downward pressure on the prices of branded medicines.

To know more about pricing and market access trends, download a free report sample

Pharma Pricing and Reimbursement and Market Access Risk - Regional Overview

The key regions considered for pharma pricing and reimbursement and market access risk are Latin America, North America, Europe, Asia-Pacific, and Middle East & Africa.

Latin America: Latin America’s improved market access was the result of some countries lifting price caps and applying changes to reimbursement mechanisms in 2022. Although these markets are maturing, the regulations put in place also tackle inflationary pressure and shortages brought about due to the war in Ukraine.

North America: In the US, pressure to control prescription drug prices has resulted in the passing of the Inflation Reduction Act, marking the first time the federal government could negotiate prices. However, in Canada, the passing of the Patented Medicine Prices Review Board (PMPRB) reforms and their ongoing effects have caused concerns over drug availability.

Europe: Many European markets in 2022 have applied significant pressure to the pharma industry in the form of cost containment measures, leading the industry to question the strength of key markets such as the UK and Germany.

Asia-Pacific: The Asia-Pacific markets continued to face challenges around pricing pressure, inflationary pressure, and drug shortages. Except for China’s expansion of essential pediatric medicine, 2022 was marked by key adjustments in the form of price controls and prolonged discussion over Japan’s pricing reform, including highly negative new “off year” price reductions.

Middle East & Africa: The Middle East & African markets saw significant changes to pricing strategies in 2022. Price hikes, reimbursement expansions, and steep changes to healthcare budgets all looked to aid market conditions against rising import costs and inflation.

For more regional insights on pharma pricing and reimbursement and market access risk, download a free report sample

Key Positive and Negative Market Access Events (October 2022 to December 2022)

Some of the key events with a positive effect on market access are as follows:

  • Slovakia’s major P&R reforms see the introduction of a new cost-effectiveness threshold for orphan drugs and advanced therapies
  • Belarusian MoH imposes moratorium on price increases for domestic medicines, medical devices, and health services

Some of the key events with a negative effect on market access are as follows:

  • Greek MoH Bill sees burden shift from clawbacks to rebates
  • Germany’s Ambulatory Oncology Drug Delivery System under scrutiny, as pharmacists question new discount rates on popular biosimilars

To know more about effect of key events on market access event risk ratings, download a free report sample

Segments Covered in the Report

Pharma Pricing and Reimbursement and Market Access Regional Outlook (2022 and 2023)

  • Latin America
  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa


Global coverage of key P&R and health policy reforms, pricing trends, and more.

Reasons to Buy

Global outlook for market access and pricing & reimbursement (P&R) in the pharmaceutical industry, including key trends that are driving opportunities and risk. The report includes our annual outlook for 2023 on the P&R and HTA policy reform environment and how that is driving GlobalData’s unique market access risk scores (MARS) which provide a quantitative framework for pricing/market access professionals to assess risk and opportunities around the world.

Key Players

Table of Contents

P&R 2022 Round-Up, 2023 Outlook 3-19

• Executive Summary 3-7

• Regional Overview 8-19

MARS first – quarter update 20

Regional Overview and country focus

• Americas 22-23

• Europe 24-25

• Asia and other regions 26-27

• Changes to MARS 28-30

• Selected positive events 31

• Selected negative events 32

Appendix: MARS methodology 33-43

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

We are confident about Pharma Pricing and Reimbursement and Market Access Risk Scores (MARS) by Region – Overview of 2022 and Outlook for 2023 report's unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pharma Pricing and Reimbursement and Market Access Risk Scores (MARS) by Region – Overview of 2022 and Outlook for 2023 in real time.

  • Access a live Pharma Pricing and Reimbursement and Market Access Risk Scores (MARS) by Region – Overview of 2022 and Outlook for 2023 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.